Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Total Long Term Debt: 2017-2020

Historic Total Long Term Debt for Dr Reddys Laboratories (RDY) over the last 1 years, with Dec 2020 value amounting to $280.0 million.

  • Dr Reddys Laboratories' Total Long Term Debt was N/A to $280.0 million in Q4 2020 from the same period last year, while for Dec 2020 it was $280.0 million, marking a year-over-year change of. This contributed to the annual value of $741.0 million for FY2018, which is N/A change from last year.
  • According to the latest figures from Q4 2020, Dr Reddys Laboratories' Total Long Term Debt is $280.0 million, which was down 25.53% from $376.0 million recorded in Q3 2020.
  • Dr Reddys Laboratories' 5-year Total Long Term Debt high stood at $793.0 million for Q2 2018, and its period low was $841 during Q3 2017.
  • For the 2-year period, Dr Reddys Laboratories' Total Long Term Debt averaged around $547.5 million, with its median value being $558.5 million (2018).
  • Data for Dr Reddys Laboratories' Total Long Term Debt shows a peak YoY grew of 7.60% (in 2018) over the last 5 years.
  • Over the past 3 years, Dr Reddys Laboratories' Total Long Term Debt (Quarterly) stood at $860 in 2017, then grew by 7.60% to $793.0 million in 2018, then reached $280.0 million in 2020.
  • Its Total Long Term Debt stands at $280.0 million for Q4 2020, versus $376.0 million for Q3 2020 and $793.0 million for Q2 2018.